Navigation Links
Despite Availability of Generic Equivalents, Two-Thirds of Neurologists Will Continue to Prescribe Branded Anti-Epileptic Drugs to Epilepsy Patients

However, AED Brands Facing Generic Competition Will be Dropped or Pushed to Tier Three of Many MCO Formularies, According to a New Report from Decision Resources

WALTHAM, Mass., Jan. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the willingness of neurologists to prescribe generic anti-epileptic drugs (AEDs) varies dramatically by indication, affording branded AEDs protection in the epilepsy market but not in other markets. Despite physicians' misgivings about the generic equivalence of AEDs, 89 percent of surveyed neurologists are willing to prescribe generic AEDs for painful diabetic neuropathy, and 84 percent are willing to prescribe AEDs for migraine prophylaxis. By contrast, only about one-third of neurologists are willing to prescribe generic AEDs for patients with partial onset epilepsy or refractory epilepsy.

The new Physician & Payer Forum report Will Prescribers and Payers Allow Branded AEDs to Stem the Tide of Generics in Epilepsy, Migraine, Neuropathic Pain or Bipolar Disorder? finds that while physicians' determination to resist generic substitution of branded AEDs at the pharmacy level varies hugely by indication, it does not vary as significantly by brand.

"Currently, 54 percent of the neurologists we surveyed specify 'no generic substitution' on prescriptions for GlaxoSmithKline's Lamictal and a similar proportion indicate they will specify the same on prescriptions for other AEDs when generic versions of these agents become available," said Kate Hohenberg, director at Decision Resources. "However, there is an exception, most significantly in epilepsy, for Abbott's Depakote ER. Our survey showed that 79 percent of neurologists will not agree to switch their epilepsy patients from the brand to the generic version of Depakote ER. Physicians' concerns are a result of this agent's narrower therapeutic index and its narrower margin for error in generic equivalence."

The report also finds that brands facing generic competition will be dropped or pushed to tier three of many managed care organizations' (MCO) formularies. After March 2009, when generic versions of UCB's Keppra, Ortho-McNeil's Topamax and Depakote ER have become available, more than half of 20 surveyed private plans will remove Keppra and Topamax from their formularies and another five plans will shift these brands to tier three. By contrast, Depakote ER will retain favorable placement in 50 percent of surveyed plans.

Will Prescribers and Payers Allow Branded AEDs to Stem the Tide of Generics in Epilepsy, Migraine, Neuropathic Pain or Bipolar Disorder? is based on a U.S. survey of 70 psychiatrists and 70 neurologists and 20 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

    Decision Resources
    Christopher Comfort

    Decision Resources, Inc.
    Elizabeth Marshall

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Despite Sagging Economy, Viamedic Reports Solid Online Sales for Erectile Dysfunction Drugs
2. Coerced medication used in psychiatric care despite lack of clinical evidence
3. Jennie Finch Shares how to Fire up the Romance Despite the Demands of the Holidays
4. Hopes for AIDS Vaccine Still Alive Despite Setbacks
5. Despite Economy, Oregon Wine Benefit !Salud! Raises Over $735,000
6. Despite national guidelines, private insurers, ER, federal and state agencies fail to routinely test for HIV
7. Triglyceride Levels Continue to Rise in the United States Despite Increased Use of Cholesterol-Lowering Medications
8. Bone cancer treatment ineffective, despite promising laboratory data
9. Despite U.S. economy, more Americans seeking cosmetic surgery overseas
10. Despite Credit Crunch, Medisave Sees Strong Sales Increase in 2008
11. Stroller Strides(R) Franchises Succeed Despite Economic Climate
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Today, Mothers Against Drunk ... roadways has dropped below 10,000 for the first time since 2011. In 2014, there ... According to data released by the National Highway Traffic Safety Administration (NHTSA), 32,675 people ...
(Date:11/25/2015)... ... ... An unlikely combination of recycled plastic shopping bags in ... to have a more dignified and comfortable night’s sleep. , Residents of Friendship ... bags into sleeping mats for the homeless. The project, according to Jeannette ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... bunion treatment, is offering lower prices in an early celebration of the early ... the promotional price of $29.95 each (normally $33.95 ea). Black Friday promotional pricing ...
(Date:11/24/2015)... ... November 24, 2015 , ... Young patients with a wide variety ... Wolfman and Dr. Kedar S. Lele, who are pediatric dentists in Tucson, AZ ... the WaterLase iPlus 2.0™ system causes minimal discomfort and bleeding to the patient during ...
(Date:11/24/2015)... ... , ... DMG Productions announced that they will feature Aphria, Inc., in an ... Channel. Dates and show times TBA. , Aphria, Inc., is a publicly traded company ... and supplying medical marijuana pursuant to the Marijuana for Medical Purposes Regulations (the “MMPR”). ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , November 25, 2015 The ... to repeated failure of IVF cycles. After failure of ... dejected and had lost all hopes that she would be able to ... miracle child conceived after failure of over 15 IVF ... (UK) before they decided to take one last attempt with Gaudium ...
(Date:11/24/2015)... CARLOS, Calif. , Nov. 24, 2015 ... a leader in non-invasive genetic testing and ... announced that it will present at the ... in New York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew ... the Company,s financial results, business activities and ...
(Date:11/24/2015)... TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ - ... NASDAQ: EPIX ) announced today that the first ... study of EPI-506 as a treatment for metastatic castration-resistant ... and Canada.  --> ... --> In the Phase 1/2 clinical trial, ESSA ...
Breaking Medicine Technology: